
Michael R Johnston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11054848/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. BMJ Open, 2019, 9, e024719.	1.9	32
2	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology, 2017, 12, 1210-1222.	1.1	112
3	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq1 1 1523-1531.	0.784314 10.7	rgBT /Overl 158
4	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. Journal of Thoracic Oncology, 2014, 9, 1449-1458.	1.1	45
5	Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. New England Journal of Medicine, 2013, 369, 910-919.	27.0	1,020
6	Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma. Journal of Immunology, 2010, 185, 956-966.	0.8	28
7	Translymphatic Chemotherapy by Intrapleural Placement of Gelatin Sponge Containing Biodegradable Paclitaxel Colloids Controls Lymphatic Metastasis in Lung Cancer. Cancer Research, 2009, 69, 1174-1181.	0.9	47
8	Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2009, 27, 1413-1418.	1.6	240
9	Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 823-829.	0.8	136
10	Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2008, 85, 1206-1210.	1.3	41
11	A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA–paclitaxel microspheres. Biomaterials, 2007, 28, 3236-3244.	11.4	79
12	Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 111-116.	0.8	76
13	Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer, 2006, 51, 377-386.	2.0	53
14	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene, 2004, 23, 6316-6324.	5.9	31
15	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer, 2004, 46, 197-204.	2.0	43
16	Stability and Heterogeneity of Expression Profiles in Lung Cancer Specimens Harvested Following Surgical Resection. Neoplasia, 2004, 6, 761-767.	5.3	43
17	Induction therapy for stage III lung cancer. Lung Cancer, 2003, 42, S53-S57.	2.0	2
18	Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene, 2002, 21, 7598-7604.	5.9	89

MICHAEL R JOHNSTON

#	Article	IF	CITATIONS
19	Validation of an orthotopic model of human lung cancer with regional and systemic metastases. Annals of Thoracic Surgery, 2001, 71, 1120-1125.	1.3	16
20	Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clinical and Experimental Metastasis, 1999, 17, 157-162.	3.3	37
21	Curable lung cancer. Postgraduate Medicine, 1997, 101, 155-165.	2.0	7
22	Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 368-373.	0.8	98
23	Tolerance of the isolated perfused lung to hyperthermia. Journal of Thoracic and Cardiovascular Surgery, 1991, 101, 732-739.	0.8	28
24	Pulmonary toxicity of doxorubicin administered byin situ isolated lung perfusion in dogs. Cancer, 1988, 61, 1320-1325.	4.1	35
25	Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. Journal of Thoracic and Cardiovascular Surgery, 1984, 87, 260-268.	0.8	178
26	Isolated lung perfusion with adriamycin. A preclinical study. Cancer, 1983, 52, 404-409.	4.1	45
27	Survival Following Aggressive Resection of Pulmonary Metastases from Osteogenic Sarcoma: Analysis of Prognostic Factors. Annals of Thoracic Surgery, 1983, 36, 516-523.	1.3	166
28	Median sternotomy for resection of pulmonary metastases. Journal of Thoracic and Cardiovascular Surgery, 1983, 85, 516-522.	0.8	103